Ipilimumab-induced endocrinopathies: When to start corticosteroids (or not)

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 2, 2013, Pages 489-490

  Corsello, Salvatore Maria ^a   Salvatori, Roberto ^b   Barnabei, Agnese ^c   De Vecchis, Liana ^d   Marchetti, Paolo ^e   Torino, Francesco ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IPILIMUMAB; METHYLPREDNISOLONE; PREDNISONE;

ADRENAL INSUFFICIENCY; CANCER CHEMOTHERAPY; CORTICOSTEROID THERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDICATION; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ENDOCRINE OPHTHALMOPATHY; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSITIS; HYPOPITUITARISM; LETTER; PRIORITY JOURNAL; SIDE EFFECT; THYROID DISEASE; THYROID FUNCTION TEST; THYROIDITIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ENDOCRINE SYSTEM DISEASES; HUMANS; HYPOPITUITARISM; METHYLPREDNISOLONE; NEOPLASMS; PREDNISONE; THYROID DISEASES;

EID: 84880916713     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2213-y     Document Type: Letter

References (11)

1. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F (2013) Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98:1361-1375
2. Torino F, Barnabei A, De Vecchis L, Salvatori R, Corsello SM (2012) Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 17:525-535
3. Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691-2697
4. Yervoy (ipilimumab): serious and fatal immune-mediated adverse reactions. www.yervoy.com/hcp/rems
5. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM (2005) Cytotoxic T-lymphocyte associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593-598 (Pubitemid 41533093)
6. Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB (2012) Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 167:1-5
7. Min L, Vaidya A, Becker C (2012) Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract 18:351-355
8. Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR (2009) Ipilimumab-induced hypophysitis: MR imaging findings. AJNR Am J Neuroradiol 30:1751-1753
9. Hamnvik OP, Larsen PR, Marqusee E (2011) Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 103:1572-1587
10. Min L, Vaidya A, Becker C (2011) Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 164:303-307
11. Borodic G, Hinkle DM, Cia Y (2011) Drug-induced Graves' disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 27:e87-e88